Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROIHSTOP: Abrupt Discontinuation vs Gradual Tapering of Propranolol in Infantile Hemangioma
NCT07665177Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of propranolol in infantile hemangioma (IH) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of Rebound Growth Following Propranolol Discontinuation at 3 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
propranolol
03
Conditions
infantile hemangioma (IH)
Beyond the preview
Go deeper on NCT07665177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665177.